|Mr. William H. Collier||Pres, CEO & Director||972.32k||N/A||1960|
|Dr. Michael J. Sofia||Chief Scientific Officer||637.75k||N/A||1958|
|Mr. Michael J. McElhaugh||Chief Bus. Officer||603.42k||N/A||1974|
|Mr. David C. Hastings||CFO & Chief Accounting Officer||N/A||N/A||1961|
|Pam Murphy||Investor Relations Consultant||N/A||N/A||N/A|
|Dr. Elizabeth Howard||Exec. VP, Gen. Counsel, Chief Compliance Officer & Sec.||N/A||N/A||1954|
|Dr. Gaston Picchio Ph.D.||Chief Devel. Officer||N/A||N/A||1963|
|Mr. R. Hector Mackay-Dunn B.A., L.L.B., Q.C., J.D., Q.C||Sec.||N/A||N/A||1951|
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Arbutus Biopharma Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.